ublituximab
Selected indexed studies
- Ublituximab versus Teriflunomide in Relapsing Multiple Sclerosis. (N Engl J Med, 2022) [PMID:36001711]
- Ublituximab. (, 2006) [PMID:36701507]
- Ublituximab: First Approval. (Drugs, 2023) [PMID:36920653]
_Worker-drafted node — pending editorial review._
Connections
ublituximab is a side effect of
Sources
- Ublituximab versus Teriflunomide in Relapsing Multiple Sclerosis. (2022) pubmed
- Ublituximab. (2006) pubmed
- Ublituximab: First Approval. (2023) pubmed
- Ublituximab. (2012) pubmed
- PMID:39883826 (2024) pubmed
- Ublituximab-xiiy as a treatment option for relapsing multiple sclerosis. (2023) pubmed
- Comparative efficacy and tolerability of ublituximab vs. other monoclonal antibodies in the treatment of relapsing multiple sclerosis: a systematic review and network meta-analysis of randomized trials. (2024) pubmed
- Ublituximab-xiiy. (2023) pubmed
- Outcomes of Ublituximab compared to Teriflunomide for relapsing multiple sclerosis: A meta-analysis. (2022) pubmed
- PMID:39808029 (2024) pubmed